Search Results - combination+therapy

3 Results

Sort By:

Photoactivatable Lipid-based Nanoparticles as a Vehicle for Dual Agent Delivery

Abstract: The invention relates to novel lipid-based nanoparticles (liposomes) for use in targeted, on demand and on site drug delivery. The particles include a wall surrounding a cavity, wherein the wall is comprised of: A lipid bilayer comprising 1,2-bis(tricosa-10,12-diynoyl)-sn-glycero-3-phosphocholine (DC8,9PC), dipalmitoylphosphatidylcholine...

Published: 4/22/2025 | Inventor(s): Anu Puri, Robert Blumenthal, Amit Joshi, Darayash Tata, Mathias Viard

Keywords(s): Combination Therapy, Delivery Agent, Infections (bacteria and viruses), Lipid nanoparticle, liposome, On-demand Drug Release, photoactivation, therapeutic delivery

Category(s): TherapeuticArea > Infectious Disease, TherapeuticArea > Dermatology, Application > Therapeutics, Collaboration Sought > Collaboration, TherapeuticArea > Oncology, Collaboration Sought > Licensing, TherapeuticArea > Cardiology, TherapeuticArea > Ear, Nose, & Throat, TherapeuticArea > Ophthalmology

Combination of Near Infrared Photoimmunotherapy Targeting Cancer Cells and Host-Immune Activation

Abstract: Common methods of cancer therapy largely rely on either direct killing of cancer cells or activation of the host immune response to do so, but not both. A recently developed treatment of tumors uses an antibody/photo-absorber, Ab-IR700, with near infrared photoimmunotherapy (NIR-PIT), to selectively kill IR700-bound and NIR-light-exposed cancer...

Published: 4/24/2025 | Inventor(s): Hisataka Kobayashi, Peter Choyke

Keywords(s): antibody-IR700, Combination Therapy, Immunomodulators, Immunotherapy, Kobayashi, Metastasis, Near-Infrared Photo Immunotherapy, NIR-PIT, Photochemical, Tumor Inhibition

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology

Highly Potent and Selective Deubiquitinating Enzyme Inhibitor

Available for licensing are inhibitors that target the USP1/ UAF1 deubiquitinating enzyme (DUB) complex. The FDA approval and commercial success of Velcade®, a small molecule proteasome inhibitor, has established the ubiquitin-proteasome system (UPS) as a valid target for anticancer treatment. However, proteasome inhibitors in general suffer from...

Published: 10/28/2024 | Inventor(s): Andrew Rosenthal, Ajit Jadhav, Thomas Dexheimer, Anton Simeonov, Qin Liang, Zhihao Zhuang, David Maloney

Keywords(s): CANCER, CANCER THERAPEUTICS, CB5XXX, CB7XXX, CBXXXX, Combination Therapy, CXXXXX, Deubiquitinase, Inhibitors, POTENT, protease inhibitors, SELECTIVE, small molecule, USP1/UAF1

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Therapeutics